Differences in IgG antibody responses following BNT162b2 and mRNA-1273 Vaccines

Abstract

Studies examining antibody responses by vaccine brand are lacking and may be informative for optimizing vaccine selection, dosage, and regimens. The purpose of this study is to assess IgG antibody responses following immunization with BNT162b2 (30 μg S protein) and mRNA-1273 (100 μg S protein) vaccines. A cohort of clinicians at a non-for-profit organization is being assessed clinically and serologically following immunization with BNT162b2 or mRNA-1273. IgG responses were measured at the Remington Laboratory by an IgG against the SARS-CoV-2 spike protein-receptor binding domain. Mixed-effect linear (MEL) regression modeling was used to examine whether the SARS-CoV-2 IgG level differed by vaccine brand, dosage, or days since vaccination. Among 532 SARS-CoV-2 seronegative participants, 530 (99.6%) seroconverted with either vaccine. After adjustments for age and gender MEL regression modeling revealed that the average IgG increased after the second dose compared to the first dose (p<0.001). Overall, titers peaked at week six for both vaccines. Titers were significantly higher for mRNA-1273 vaccine on days 14-20 (p < 0.05), 42-48 (p < 0.01), 70-76 (p < 0.05), 77-83 (p < 0.05), and higher for BNT162b2 vaccine on days 28-34 (p < 0.001). In two participants taking immunosuppressive drugs SARS-CoV-2 IgG remained negative. The mRNA-1273 vaccine elicited both earlier antibody responses than BNT162b2 and higher antibody levels, possibly due to the higher S-protein delivery. Prospective clinical and serological follow-up of defined cohorts such as this may prove useful in determining antibody protection and whether differences in antibody kinetics between the vaccines have clinical significance.

The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2

“…Complementing data comparing peak antibody levels of the BNT162b2 mRNA vaccine to that of natural infection ( 14 ), our literature search yielded nine additional studies that provided a common temporal and assay basis for comparative analysis. These studies comprise a total of 14 comparisons of anti-RBD, anti-S1, or anti-S IgG antibodies following vaccination between BNT162b2 and three other vaccines ( Table 1 ): 6 comparisons between BNT162b2 and mRNA-1273 ( 38 – 43 ), 4 comparisons between BNT162b2 and ChAdOx1 ( 38 , 39 , 44 , 45 ), and 4 comparisons between BNT162b2 and Ad26.COV2.S ( 40 , 42 , 43 ). Data from Horndler ( 38 ) regarding Ad26.COV2.S were excluded, as the duration of antibody response reported for the vaccine did not include the peak.…”

“…3 individuals sampled 2 wk after BNT162b2 vaccination and 29 individuals sampled 2 wk after mRNA-1273 vaccination ( 41 )…”

Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection

“…The first post‐vaccine sample was obtained from 477 healthcare workers [Moderna 175 (36.69%) and Pfizer 302 (63.31%)] 2 months after the second dose ±7 days (months of April, May and June 2021), shortly after the peak of antibodies was reached (Montoya et al, 2021).…”

Demonstration of antibodies against SARS-CoV-2, neutralizing or binding, in seroconversion panels after mRNA-1273, BNT-162b2 and Ad26.COV2.S vaccine administration

“…The mRNA-1273 vaccine 100 μg of pre-fusion-stabilized spike glycoprotein mRNA given as two doses four weeks apart. [2]…”

“…The mRNA-1273 vaccine 100 μg of pre-fusion-stabilized spike glycoprotein mRNA given as two doses four weeks apart. [2] The BNT-162B2 vaccine (Comirnaty®, BioNTech, Mainz, Germany/Pfizer, New York, NY, USA ) was first utilized under an EUA beginning December 11, 2020 [3] and became the first COVID-19 vaccine approved by the FDA on August 23, 2021. It was approved for the prevention of COVID-19 in individuals 16 years of age and older.…”